Dr. Fenton received undergraduate training at the University of Cincinnati, graduating with a BS in Biology. He then attended NYU School of Medicine as part of the MD/Ph.D. program, graduating in 1983. His Ph.D. dissertation described the transcription of viral genes in Polyoma virus-transformed cells. He then undertook Internal Medicine training at the Brigham and Woman’s Hospital followed by an Oncology Fellowship at the Dana-Farber Cancer Institute. He received post-doctoral research training in the Department of Genetics, Harvard Medical School.


After training, Dr. Fenton began his professional career as a Senior Investigator at the NCI in Frederick, Maryland. He was PI of a lab studying cancer vaccines and developed a number of Phase I studies using cancer vaccines in renal cell and melanoma. Clinical responsibilities included outpatient care of patients with non-Hodgkin Lymphoma, Hodgkin Disease, Hairy Cell Leukemia, melanoma, and renal cell cancer and attending on the clinical research ward.

After the NCI closed the program at the Frederick facility, Dr. Fenton became an Associate Professor of Medicine at the University of Maryland Greenebaum Cancer Center. He was an attending physician on the Stem Cell Transplant Service and performed laboratory studies aimed at identifying novel therapeutic targets in Multiple Myeloma. He was funded by a number of peer-reviewed research grants, trained post-doctoral fellows, medical interns, and residents, and published a number of papers in upper level scientific and medical journals. His clinical responsibilities evolved to attending on the Adult Leukemia Service, and then became a Clinical Investigator and PI on the Gastrointestinal Cancer Service. As a member of the Cancer Center, clinical responsibilities included close interactions with the clinical research team, as well as writing protocols, interacting with investigators at other research sites, monitoring the safety of subjects in clinical trials, and submitting SAEs to health authorities as required, etc. During this period, Dr. Fenton was a member of the Experimental Therapeutics Study Section of NCI, performing quarterly reviews of R01, R21, and P01 grants submitted by academic researchers to NIH.

Dr. Fenton was recruited to the National Institute on Aging, NIH, where he was involved with research in changes in metabolism and muscle physiology in the elderly, and designed a randomized Phase II study of resveratrol to study its effects on muscle physiology with the hope of improving strength and mobility of elderly subjects. This was followed by a brief period of Private Practice, but Dr. Fenton chose to get back into clinical research.

For the past 8 years, Dr. Fenton has worked as a consultant for large and small pharmaceutical companies and CROs. The work has encompassed a number of medical fields including oncology, infectious disease (e.g. HIV/AIDS), congenital diseases, and other Rare Diseases with Orphan Drug candidates. During this time his expertise has come to include Medical Monitoring of clinical studies, including SUSAR determination and submission to Health Authorities per ICH guidelines, and speaking directly with clinical site investigators or other members of the clinical team when necessary.  He has written a number of clinical protocols including randomized, international Phase III studies in early-stage bladder cancer that are now accruing patients. Additionally, he has authored or participated in writing numerous regulatory documents including pre-IND, IND, clinical study reports, Orphan Drug Applications to the FDA and EU, and a number of clinical protocols as mentioned. He has been involved in numerous high-level meetings with Health Authorities, helped arrange and participated in pre-IND meetings and Investigator Meetings, and had numerous close interactions with clinical research members during the development and implementation stages of clinical trials.

Dr. Fenton continues efforts to help bring novel therapeutic agents to the patients in greatest need. He continues to read extensively the medical and scientific literature so that he can make novel and important contributions to the clinical research team.